NickieToTheT schreef op 2 januari 2020 15:40:
Dat wat er al zit heb je dus.
Nu de eu. In combinatie met in de toekomst twee indicaties(more likely then not) zal dat Pharming goed doen.
Sijmen de Vries, Chief Executive of Pharming, said:
“Our strategic decision to reacquire the commercial rights to RUCONEST® from Sobi builds
on the commercial success of the product in the US and now means we own commerical
rights to our lead asset for the treatment of HAE in all countries, except some markets in
Latin America, Israel and South Korea. The transaction will enable us to drive further growth
of RUCONEST® and will be accretive to earnings immediately. In addition, we will expand our
existing commercial infrastructure in Europe to support the expected launch of future new
products from our pipeline, including the recently in-licensed, late-stage compound,
leniolisib, for the treatment of APDS.”